Joseph A. Bovi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joseph A. Bovi has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Alissa A. Thomas
University of Vermont Larner College of Medicine, Burlington, VT
3 shared publications - Camilo E. Fadul
Division of Neuro-Oncology, Department of Neurology, University of Virginia, Charlottesville, Virginia, USA
3 shared publications Christopher J. Schultz
Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
3 shared publications- Cliff Grant Robinson
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
2 shared publications Jennifer M. Connelly
Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin
2 shared publications- John H. Suh
Cleveland Clinic, Cleveland, OH
2 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 1946-1952
Palliative Care and Quality Outcomes in Patients With Brain Metastases and Poor Prognosis: A Multi-Institutional Analysis
PURPOSE: To analyze the patterns of palliative care (PC) consultation for patients with brain metastases (BMETs) and its association with treatment, overall survival (OS), and quality metrics (eg, advance directives [ADs], hospice enrollment). METHODS: We performed a multi-institutional retrospective quality review of consecutive patients diagnosed with BMETs from 2017 to 2019. We collected patient demographics, cancer diagnosis, performance status, treatment, PC consultation, emergency department utilization, AD completion, hospice enrollment, and OS data. We included patients with a predicted survival of P < .0001) and to enroll in hospice ( P < .0001). CONCLUSION: The involvement of PC services correlated with higher completion rates of ADs and increased hospice utilization, without compromising survival or significantly altering other treatment options. There is an unmet need for PC among patients with BMETs with poor prognosis.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (11) , 1946-1952
Palliative Care and Quality Outcomes in Patients With Brain Metastases and Poor Prognosis: A Multi-Institutional Analysis
PURPOSE: To analyze the patterns of palliative care (PC) consultation for patients with brain metastases (BMETs) and its association with treatment, overall survival (OS), and quality metrics (eg, advance directives [ADs], hospice enrollment). METHODS: We performed a multi-institutional retrospective quality review of consecutive patients diagnosed with BMETs from 2017 to 2019. We collected patient demographics, cancer diagnosis, performance status, treatment, PC consultation, emergency department utilization, AD completion, hospice enrollment, and OS data. We included patients with a predicted survival of P < .0001) and to enroll in hospice ( P < .0001). CONCLUSION: The involvement of PC services correlated with higher completion rates of ADs and increased hospice utilization, without compromising survival or significantly altering other treatment options. There is an unmet need for PC among patients with BMETs with poor prognosis.
- 27 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2169-2175
Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma
NRG Oncology RTOG 0539 was a prospective phase II trial of risk-adapted radiotherapy for patients with WHO grade 1-3 meningioma. Low-risk (group 1, n = 60) was defined as a grade 1 tumor after gross total resection or subtotal resection (GTR/STR) and prospectively monitored. Intermediate-risk (group 2, n = 52) was defined as recurrent grade 1 or newly diagnosed grade 2 tumor after GTR and treated with radiotherapy (54 Gy). High-risk (group 3, n = 53) included a newly diagnosed grade 2 tumor after STR, newly diagnosed grade 3 tumor, or recurrent grade 2 or 3 tumor and treated with radiotherapy (60 Gy). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The median follow-up times for the low-, intermediate-, and high-risk cohorts were 12.1, 12.0, and 11.1 years, respectively. The 10-year PFS and OS rates for the low-, intermediate-, and high-risk cohorts were 85.2% and 94.1%, 72.2% and 84.7%, and 42.5% and 51.1%, respectively. Five patients (9.6%) and eight patients (15.1%) had a grade 3+ toxicity attributed to radiotherapy in the intermediate- and high-risk cohorts, respectively. The long-term outcomes using this risk-adapted approach support observation for low-risk patients, inform radiotherapy patient selection and practice standards for intermediate- and high-risk patients, and provide comparative benchmarks for future trials.
- 27 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2169-2175
Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma
NRG Oncology RTOG 0539 was a prospective phase II trial of risk-adapted radiotherapy for patients with WHO grade 1-3 meningioma. Low-risk (group 1, n = 60) was defined as a grade 1 tumor after gross total resection or subtotal resection (GTR/STR) and prospectively monitored. Intermediate-risk (group 2, n = 52) was defined as recurrent grade 1 or newly diagnosed grade 2 tumor after GTR and treated with radiotherapy (54 Gy). High-risk (group 3, n = 53) included a newly diagnosed grade 2 tumor after STR, newly diagnosed grade 3 tumor, or recurrent grade 2 or 3 tumor and treated with radiotherapy (60 Gy). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The median follow-up times for the low-, intermediate-, and high-risk cohorts were 12.1, 12.0, and 11.1 years, respectively. The 10-year PFS and OS rates for the low-, intermediate-, and high-risk cohorts were 85.2% and 94.1%, 72.2% and 84.7%, and 42.5% and 51.1%, respectively. Five patients (9.6%) and eight patients (15.1%) had a grade 3+ toxicity attributed to radiotherapy in the intermediate- and high-risk cohorts, respectively. The long-term outcomes using this risk-adapted approach support observation for low-risk patients, inform radiotherapy patient selection and practice standards for intermediate- and high-risk patients, and provide comparative benchmarks for future trials.
- 14 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1654-1662
Hospital Admission and Survival of Patients With Brain Metastases Diagnosed in the Emergency Care Setting
PURPOSE: Brain metastases (BMETS) are commonly diagnosed in emergency care setting (ECS)—such as the emergency department (ED) or after direct admissions—yet research on their admission patterns, management, and survival is limited. This study examines the clinical course, outcomes, and potential impact of an admission algorithm for patients diagnosed with BMETS in ECS. METHODS: This is a retrospective study conducted across three academic hospitals, analyzing admissions and survival of BMETS patients in ECS. Patients were age at least 18 years with imaging-confirmed BMETS. We developed an admission algorithm that was retrospectively applied to assess the rationale for hospitalization. Primary outcomes included admission rates, length of stay (LOS) in the ED and hospital, and overall survival. RESULTS: Among 312 patients, 250 had brain imaging available at initial ECS presentation; 241 (96.4%) were admitted. Median ED LOS was 7 hours, increasing with multiple imaging studies ( P < .001) and consults ( P = .01). Median hospital LOS was 6.7 days, prolonged by inpatient interventions (9.9 v 6.2 days, P < .001) and poor functional status (8.6 v 5.4 days, P < .001). Median survival post-discharge was 4.4 months, influenced by functional status ( P < .001) and comorbidities ( P = .004). Applying the admission algorithm, 224 (89.6%) required hospitalization while 26 (10.4%) were eligible for outpatient care. CONCLUSION: BMETS patients in ECS have high admission rates and poor survival. A standardized admission algorithm may reduce ED LOS by identifying patients who require hospitalization. Further research is needed to refine triage and improve outcomes.
- 14 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1654-1662
Hospital Admission and Survival of Patients With Brain Metastases Diagnosed in the Emergency Care Setting
PURPOSE: Brain metastases (BMETS) are commonly diagnosed in emergency care setting (ECS)—such as the emergency department (ED) or after direct admissions—yet research on their admission patterns, management, and survival is limited. This study examines the clinical course, outcomes, and potential impact of an admission algorithm for patients diagnosed with BMETS in ECS. METHODS: This is a retrospective study conducted across three academic hospitals, analyzing admissions and survival of BMETS patients in ECS. Patients were age at least 18 years with imaging-confirmed BMETS. We developed an admission algorithm that was retrospectively applied to assess the rationale for hospitalization. Primary outcomes included admission rates, length of stay (LOS) in the ED and hospital, and overall survival. RESULTS: Among 312 patients, 250 had brain imaging available at initial ECS presentation; 241 (96.4%) were admitted. Median ED LOS was 7 hours, increasing with multiple imaging studies ( P < .001) and consults ( P = .01). Median hospital LOS was 6.7 days, prolonged by inpatient interventions (9.9 v 6.2 days, P < .001) and poor functional status (8.6 v 5.4 days, P < .001). Median survival post-discharge was 4.4 months, influenced by functional status ( P < .001) and comorbidities ( P = .004). Applying the admission algorithm, 224 (89.6%) required hospitalization while 26 (10.4%) were eligible for outpatient care. CONCLUSION: BMETS patients in ECS have high admission rates and poor survival. A standardized admission algorithm may reduce ED LOS by identifying patients who require hospitalization. Further research is needed to refine triage and improve outcomes.
- 10 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (32) , 3516-3525
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003
PURPOSE: Hippocampal avoidance (HA) during therapeutic whole-brain radiotherapy reduces the risk of neurocognitive function (NCF) toxicity in patients with brain metastasis. This trial hypothesized that HA during prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) leads to noninferior intracranial relapse (ICR) and reduction in NCF toxicity. METHODS: This randomized phase II/III trial enrolled patients with SCLC, no brain metastases, and response to chemotherapy. The primary end points were 12-month ICR (noninferiority design, randomized phase II) and 6-month Hopkins Verbal Learning Test–Revised (HVLT-R) Delayed Recall (DR) failure (phase III). Secondary end points were failure in any NCF test, health-related quality of life (HRQOL), overall survival (OS), and toxicity. RESULTS: From December 2015 to June 2022, 393 patients were randomly assigned. The median age was 64 years. Stage and memantine usage were balanced. The median follow-up was 17.0 months (all patients) and 30.8 months (alive patients). HA-PCI had noninferior 12-month ICR rate (PCI 14.8% v HA-PCI 14.7%, P < .0001). Six-month HVLT-R DR deterioration was not significantly different (PCI 30.0% v HA-PCI 25.5%, P = .28). Addition of HA to PCI reduced the risk of failure in any NCF test (adjusted hazard ratio [HR], 0.78; 95% CI [0.61 to 0.99]; P = .039). Addition of HA to PCI was not associated with longitudinal change in any HRQOL domain. There were no differences in OS (adjusted HR, 0.88 [95% CI, 0.67 to 1.14]; P = .33) or grade ≥3 toxicity (PCI 31.4% v HA-PCI 30.7%, P = .88). CONCLUSION: Although the study did not meet its primary end point of DR preservation, HA during PCI reduces the risk of overall neurocognitive toxicity with noninferior ICR risk and similar survival.
- 10 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (32) , 3516-3525
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003
PURPOSE: Hippocampal avoidance (HA) during therapeutic whole-brain radiotherapy reduces the risk of neurocognitive function (NCF) toxicity in patients with brain metastasis. This trial hypothesized that HA during prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) leads to noninferior intracranial relapse (ICR) and reduction in NCF toxicity. METHODS: This randomized phase II/III trial enrolled patients with SCLC, no brain metastases, and response to chemotherapy. The primary end points were 12-month ICR (noninferiority design, randomized phase II) and 6-month Hopkins Verbal Learning Test–Revised (HVLT-R) Delayed Recall (DR) failure (phase III). Secondary end points were failure in any NCF test, health-related quality of life (HRQOL), overall survival (OS), and toxicity. RESULTS: From December 2015 to June 2022, 393 patients were randomly assigned. The median age was 64 years. Stage and memantine usage were balanced. The median follow-up was 17.0 months (all patients) and 30.8 months (alive patients). HA-PCI had noninferior 12-month ICR rate (PCI 14.8% v HA-PCI 14.7%, P < .0001). Six-month HVLT-R DR deterioration was not significantly different (PCI 30.0% v HA-PCI 25.5%, P = .28). Addition of HA to PCI reduced the risk of failure in any NCF test (adjusted hazard ratio [HR], 0.78; 95% CI [0.61 to 0.99]; P = .039). Addition of HA to PCI was not associated with longitudinal change in any HRQOL domain. There were no differences in OS (adjusted HR, 0.88 [95% CI, 0.67 to 1.14]; P = .33) or grade ≥3 toxicity (PCI 31.4% v HA-PCI 30.7%, P = .88). CONCLUSION: Although the study did not meet its primary end point of DR preservation, HA during PCI reduces the risk of overall neurocognitive toxicity with noninferior ICR risk and similar survival.
- Open Access
- 27 June 2023
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (1) , 101304
Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy
- 27 June 2023
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (1) , 101304
Open AccessCystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy
- Open Access
Relevance of the Updated Recursive Partitioning Analysis (U-RPA) Classification in the Contemporary Care of Patients with Brain Metastases
Patients with brain metastases (BMETS) need information about the prognosis and potential value of treatment options to make informed therapeutic decisions, but tools to predict survival in contemporary practice are scarce. We propose an Updated Recursive Partitioning Analysis (U-RPA) instrument to predict survival and benefit from brain-directed treatment (BDT) of contemporary patients. This was a retrospective analysis of patients with BMETS treated between 2017 and 2019. With survival as the primary endpoint, we calculated the U-RPA and generated estimates using Kaplan–Meier curves and hazard ratios. Of 862 eligible patients, 752 received BDT and 110 received best supportive care (BSC). Median overall survival with BDT and BSC was 9.3 and 1.3 months, respectively. Patients in RPA class 1, 2A, 2B and 3 who underwent BDT had median survival of 28.1, 14.7, 7.6 and 3.3 months, respectively. The median survival for patients in RPA 3 who received BDT (n = 147), WBRT (n = 79) and SRS (n = 54) was 3.3, 2.9 and 4.1 months, respectively. The U-RPA defines prognosis estimates, independent of tumor type and treatment modality, which can assist to make value-based care treatment decisions. The prognosis for patients in U-RPA class 2B and 3 remains poor, with consideration for early palliative care involvement in these cases.
Open AccessRelevance of the Updated Recursive Partitioning Analysis (U-RPA) Classification in the Contemporary Care of Patients with Brain Metastases
Patients with brain metastases (BMETS) need information about the prognosis and potential value of treatment options to make informed therapeutic decisions, but tools to predict survival in contemporary practice are scarce. We propose an Updated Recursive Partitioning Analysis (U-RPA) instrument to predict survival and benefit from brain-directed treatment (BDT) of contemporary patients. This was a retrospective analysis of patients with BMETS treated between 2017 and 2019. With survival as the primary endpoint, we calculated the U-RPA and generated estimates using Kaplan–Meier curves and hazard ratios. Of 862 eligible patients, 752 received BDT and 110 received best supportive care (BSC). Median overall survival with BDT and BSC was 9.3 and 1.3 months, respectively. Patients in RPA class 1, 2A, 2B and 3 who underwent BDT had median survival of 28.1, 14.7, 7.6 and 3.3 months, respectively. The median survival for patients in RPA 3 who received BDT (n = 147), WBRT (n = 79) and SRS (n = 54) was 3.3, 2.9 and 4.1 months, respectively. The U-RPA defines prognosis estimates, independent of tumor type and treatment modality, which can assist to make value-based care treatment decisions. The prognosis for patients in U-RPA class 2B and 3 remains poor, with consideration for early palliative care involvement in these cases.
- Open Access
Quality of Life and Cognitive Function Evaluations and Interventions for Patients with Brain Metastases in the Radiation Oncology Clinic
Brain metastases (BMs) account for a disproportionately high percentage of cancer morbidity and mortality. Historically, studies have focused on improving survival outcomes, and recent radiation oncology clinical trials have incorporated HRQOL and cognitive assessments. We are now equipped with a battery of assessments in the radiation oncology clinic, but there is a lack of consensus regarding how to incorporate them in modern clinical practice. Herein, we present validated assessments for BM patients, current recommendations for future clinical studies, and treatment advances that have improved HRQOL and cognitive outcomes for BM patients.
Open AccessQuality of Life and Cognitive Function Evaluations and Interventions for Patients with Brain Metastases in the Radiation Oncology Clinic
Brain metastases (BMs) account for a disproportionately high percentage of cancer morbidity and mortality. Historically, studies have focused on improving survival outcomes, and recent radiation oncology clinical trials have incorporated HRQOL and cognitive assessments. We are now equipped with a battery of assessments in the radiation oncology clinic, but there is a lack of consensus regarding how to incorporate them in modern clinical practice. Herein, we present validated assessments for BM patients, current recommendations for future clinical studies, and treatment advances that have improved HRQOL and cognitive outcomes for BM patients.
- 26 August 2022
- Published by Elsevier
- p. 809-819
Neuroimaging issues in assessing glioma response to brain tumour therapy
- 26 August 2022
- Published by Elsevier
- p. 809-819
Neuroimaging issues in assessing glioma response to brain tumour therapy
- Open Access
- 9 April 2022
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 5 (2) , ooac025
Department-focused electronic health record thrive training
A novel approach of department-focused electronic health record (EHR) training was implemented to improve efficiency and time management of EHR use. Based off baseline log data, 5 in-person training sessions were designed, focusing on the common inefficiencies of 6 chosen participants. Log data of 4 key metrics and 2 efficiency scores were analyzed 4 months post-training. A survey was conducted to assess self-reported EHR competence. Individually, several participants had improved efficiency scores. There was a reduced average time spent in the inbox per day, in notes per dictation, and in notes per day. This translated to an average of 8.9 min saved per day (range 0–29.1 min/day) and 37.1 hours saved per year (range 0–116.2 hours/year). From the post-training surveys, all participants felt more efficient in their use of the EHR. This study demonstrates an example of department-focused EHR training and log-based analysis improving time management and efficiency.
- 9 April 2022
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 5 (2) , ooac025
Open AccessDepartment-focused electronic health record thrive training
A novel approach of department-focused electronic health record (EHR) training was implemented to improve efficiency and time management of EHR use. Based off baseline log data, 5 in-person training sessions were designed, focusing on the common inefficiencies of 6 chosen participants. Log data of 4 key metrics and 2 efficiency scores were analyzed 4 months post-training. A survey was conducted to assess self-reported EHR competence. Individually, several participants had improved efficiency scores. There was a reduced average time spent in the inbox per day, in notes per dictation, and in notes per day. This translated to an average of 8.9 min saved per day (range 0–29.1 min/day) and 37.1 hours saved per year (range 0–116.2 hours/year). From the post-training surveys, all participants felt more efficient in their use of the EHR. This study demonstrates an example of department-focused EHR training and log-based analysis improving time management and efficiency.
- Open Access
- 27 June 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (4) , 979-986
Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes
- 27 June 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (4) , 979-986
Open AccessPulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes